Turkish
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

liver cirrhosis/triglyceride

Bağlantı panoya kaydedilir
Sayfa 1 itibaren 35 Sonuçlar

Vitamin E and DHA-EE on NAFLD - Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial (PUVENAFLD)

Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
Background information Non-alcoholic fatty liver disease (NAFLD) is characterized by excessive fat accumulation in the liver and is defined by evidence of hepatic steatosis (via imaging or histology) and is not due to secondary liver fat accumulation from excessive alcohol consumption or hereditary

Prevalence of NAFLD and Correlation With Its Main Risk Factors Among Egyptian

Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
This study is a prospective cross-sectional Multicenter National study, will include 1080 participants with BMI ≥ 24kg/m 2 with or without elevated liver enzymes. All will be subjected to; dietary history by already prepared food quality and quantity questionnaire, anthropometric data (BMI & waist

NASH and Type 2 Diabetes: Role of the Receptor Activator of Nuclear Factor-κB (RANK) and Its Ligand (RANKL)

Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
Objectives: To show that (i) expression of mRNA and proteins of the RANKL pathway (RANK, RANKL, OPG) in liver and (ii) serum concentration of RANKL/OPG proteins are correlated with the gravity of the NAFLD. Study protocol: Identify patients with different stages of NAFLD (mere steatosis, NASH, and

Change of Adipose Tissues and Triglyceride After Bariatric Surgery or Life-style Intervention

Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
Obesity is associated with different chronic disorders such as metabolic syndrome, non-alcoholic fatty liver disease (NAFLD) and diabetes mellitus type 2 (DM2). It can be classified into mild, moderate and severe using different cut-off values of body mass index (BMI). Many interventions and

The Effect of Curcumin on Liver Fat Content in Obese Subjects

Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
The prevalence of obesity is increasing worldwide. Obesity and its associated complications represent an enormous burden for obese individuals, their families, healthcare systems and societies. Non-alcoholic fatty liver disease (NAFLD) has emerged as a frequent and serious complication of obesity.

Validation of the Second Generation of the Controlled Attenuation Parameter (CAP) Using the MRI-PDFF as Reference

Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak

The Effect Of DAAs on miRNA-122 And Insulin Resistance In Chronic HCV Patients

Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
The hepatitis C virus (HCV) is an enveloped, single-stranded positive-sense Ribo-Nucleic Acid virus which is a major cause of chronic liver diseases, including cirrhosis and hepatocellular carcinoma (HCC), and infects approximately 3 % of the world population(150-170 million). One of the countries

De Novo Lipogenesis in Severity of NAFLD

Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
The development of nonalcoholic fatty liver disease (NAFLD) progresses from a state of elevated intrahepatic triglycerides (IHTG) to liver inflammation, and ultimately, hepatic apoptosis and fibrosis. NAFLD is the most prevalent liver disease in the U.S., and there is a serious need to understand

Effect of Dulaglutide on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
OBJECTIVE Nonalcoholic fatty liver disease (NAFLD) is a public health problem in patients with type 2 diabetes mellitus (T2DM). The presence of type 2 diabetes in patients with NAFLD is a risk factor for its progression to a more severe liver disease known as nonalcoholic steatohepatitis (NASH).

Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver Disease

Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
The study is a two-arm (placebo, lanifibranor 800 mg/day), randomized (1:1), double-blind, placebo-controlled, 24-week treatment study. Sixty four patients with T2DM will be randomized, allowing for a 10% drop-out rate. The diagnosis of NAFLD on imaging will be done by measuring IHTG using the

ObeSity Related Colorectal Adenoma Risk

Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
Bowel cancer, or colorectal cancer (CRC), is the second most common cancer affecting both men and women in England. The majority of CRCs develop from a pre-cancerous type of growth in the bowel called an adenoma. Detecting and removing these adenomas is important in reducing CRC risk. A study which

Lifestyle Intervention in Fatty Liver (NAFLD)

Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
Background Non-Alcoholic Fatty Liver Disease (NAFLD), including its more pathologic consequence, non-alcoholic steatohepatitis (NASH), is believed to be the most common chronic liver disease worldwide, affecting between 6 to 37% of the population. NAFLD is a so called 'silent killer', as clinical

Prevalence of Exocrine Pancreatic Insufficiency in Patients With Decompensated Cirrhosis

Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
Exocrine pancreatic insufficiency (EPI) is defined as the inability of the pancreas to perform a normal digestive function. Habitually, it occurs as a result of a severe reduction in the secretion of pancreatic enzymes, although - less frequently - it may be due to the inability of these enzymes to

Nonalcoholic Fatty Liver Disease in Morbidly Obese Patients

Sadece kayıtlı kullanıcılar makaleleri çevirebilir
Giriş yapmak kayıt olmak
This prospective study have been approved by Taipei Medical University-Joint Institutional Review Board. The starting point for each patient is the day of surgery and the end-point is 1 year after the operation. During bariatric surgery, all patients would undergo a liver biopsy under laparoscopic
Facebook sayfamıza katılın

Bilim tarafından desteklenen en eksiksiz şifalı otlar veritabanı

  • 55 dilde çalışır
  • Bilim destekli bitkisel kürler
  • Görüntüye göre bitki tanıma
  • Etkileşimli GPS haritası - bölgedeki bitkileri etiketleyin (yakında)
  • Aramanızla ilgili bilimsel yayınları okuyun
  • Şifalı bitkileri etkilerine göre arayın
  • İlgi alanlarınızı düzenleyin ve haber araştırmaları, klinik denemeler ve patentlerle güncel kalın

Bir belirti veya hastalık yazın ve yardımcı olabilecek bitkiler hakkında bilgi edinin, bir bitki yazın ve karşı kullanıldığı hastalıkları ve semptomları görün.
* Tüm bilgiler yayınlanmış bilimsel araştırmalara dayanmaktadır

Google Play badgeApp Store badge